FRET based quantification and screening technology platform for the interactions of leukocyte function-associated...

Area of Science:

• Biochemistry
• Immunology
• Biophysics

Background:

• The interaction between LFA-1 and ICAM-1 is vital for leukocyte adhesion, inflammation, and immune responses.
• Dysregulation of LFA-1/ICAM-1 interactions is implicated in autoimmune diseases and cancer metastasis.
• Targeting the LFA-1/ICAM-1 pathway offers potential therapeutic strategies.

Purpose of the Study:

• To develop a fluorescence resonance energy transfer (FRET) based assay for quantifying the dissociation constant (Kd) of the LFA-1/ICAM-1 interaction.
• To establish a screening platform for identifying inhibitors of LFA-1/ICAM-1 binding.
• To provide a novel method for drug discovery targeting LFA-1/ICAM-1 mediated processes.

Main Methods:

• Utilized an 'in solution' steady-state FRET technique with Alexa Fluor 488-LFA-1 (donor) and Alexa Fluor 555-ICAM-1 (acceptor).
• Determined the dissociation constant (Kd) of LFA-1 and human recombinant ICAM-1 (D1-D2-Fc) using quantitative FRET analysis.
• Adapted the assay for a 96-well plate format to enable high-throughput screening of inhibitory compounds.

Main Results:

• The dissociation constant (Kd) for the LFA-1 and ICAM-1 (D1-D2-Fc) interaction was determined to be 17.93±1.34 nM.
• The FRET assay successfully functioned as a screening platform for identifying LFA-1/ICAM-1 inhibitors.
• This study represents the first application of FRET for Kd determination and inhibitor classification of the LFA-1/ICAM-1 interaction.

Conclusions:

• A robust and simple FRET-based method was established for characterizing LFA-1/ICAM-1 interactions.
• The developed assay is suitable for high-throughput screening of therapeutic agents targeting LFA-1/ICAM-1.
• This work provides a valuable tool for advancing research in immunology and developing treatments for related diseases.